NASDAQ:ENTL - Entellus Medical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.00 0.00 (0.00 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$24.00
Today's Range$24.00 - $24.00
52-Week Range$11.47 - $25.58
Average Volume178,331 shs
Market Capitalization$611.38 million
P/E RatioN/A
Dividend YieldN/A
Entellus Medical logoEntellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.

Receive ENTL News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity Ratio0.32
Current Ratio1.92
Quick Ratio1.71


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$75.18 million
Price / Sales8.21
Cash FlowN/A
Price / CashN/A
Book Value$1.87 per share
Price / Book12.83


EPS (Most Recent Fiscal Year)N/A
Net Income$-28,710,000.00
Net Margins-31.24%
Return on Equity-47.37%
Return on Assets-27.29%


Outstanding Shares25,730,000

Entellus Medical (NASDAQ:ENTL) Frequently Asked Questions

What is Entellus Medical's stock symbol?

Entellus Medical trades on the NASDAQ under the ticker symbol "ENTL."

How were Entellus Medical's earnings last quarter?

Entellus Medical Inc (NASDAQ:ENTL) posted its quarterly earnings data on Thursday, November, 3rd. The medical technology company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.13. The medical technology company had revenue of $17.90 million for the quarter, compared to analyst estimates of $17.93 million. Entellus Medical had a negative return on equity of 47.37% and a negative net margin of 31.24%. The business's revenue was up 20.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.32) earnings per share. View Entellus Medical's Earnings History.

What price target have analysts set for ENTL?

3 Wall Street analysts have issued 1 year price targets for Entellus Medical's shares. Their predictions range from $17.00 to $21.00. On average, they expect Entellus Medical's share price to reach $19.00 in the next twelve months. View Analyst Ratings for Entellus Medical.

Who are Entellus Medical's key executives?

Entellus Medical's management team includes the folowing people:
  • Robert S. White, President, Chief Executive Officer, Director
  • Brent A. Moen, Chief Financial Officer, Corporate Secretary
  • Michael H. Rosenthal, Chief Operating Officer
  • Jonelle R. Burnham, Chief Compliance Officer, Vice President, General Counsel
  • Stephen R. Paidosh, Vice President, Operations
  • Thomas D. Williamson, Vice President - Sales
  • Kevin L. Mensink, Vice President of Marketing
  • Martha J. Christian, Vice President, Reimbursement
  • Timothy B. Petrick, Vice President, Research and Development
  • Brian E. Farley, Non-Executive Chairman of the Board

When did Entellus Medical IPO?

(ENTL) raised $70 million in an initial public offering on Friday, January 30th 2015. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Piper Jaffray acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Has Entellus Medical been receiving favorable news coverage?

Press coverage about ENTL stock has been trending positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Entellus Medical earned a media sentiment score of 0.44 on Accern's scale. They also assigned headlines about the medical technology company an impact score of 47.78 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Entellus Medical?

Shares of ENTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Entellus Medical's stock price today?

One share of ENTL stock can currently be purchased for approximately $24.00.

How big of a company is Entellus Medical?

Entellus Medical has a market capitalization of $611.38 million and generates $75.18 million in revenue each year. Entellus Medical employs 280 workers across the globe.

How can I contact Entellus Medical?

Entellus Medical's mailing address is 3600 Holly Ln N Ste 40, PLYMOUTH, MN 55447-1286, United States. The medical technology company can be reached via phone at +1-763-4631595.

MarketBeat Community Rating for Entellus Medical (ENTL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  178 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  315
MarketBeat's community ratings are surveys of what our community members think about Entellus Medical and other stocks. Vote "Outperform" if you believe ENTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.